Treatment and Diagnostics of the Inhibitor Form of Hemophilia in the Republic of Uzbekistan

Authors

  • Juraeva Nodira Tukhtapulatovna, Doctoral student Republican Specialized Scientific and Practical Medical Center of Hematology, Tashkent, Uzbekistan
  • Mahmudova Aziza Dzhumanovna, Doctor of Medical Sciences Republican Specialized Scientific and Practical Medical Center of Hematology, Tashkent, Uzbekistan
  • Ismoilova Zulfiya Abdufattokhovna, Candidate of Medical Sciences Republican Specialized Scientific and Practical Medical Center of Hematology, Tashkent, Uzbekistan

Abstract

The production of blocking antibodies to factor VIII and IX drugs is one of the most serious problems in the treatment of hemophilia. The development of an inhibitor leads to insufficient effectiveness of substitution therapy, sharply worsens the quality of life, and significantly increases the cost of treating patients with hemophilia [1]. Inhibitory hemophilia is an acutely developed pathological condition characterized by a violation of blood coagulation as a result of the detection of an inhibitor of disease VIII / IX, spontaneous and / or post-traumatic bleeding, identified in life threatening, in patients without previous cases of hemostasis. The appearance of an inhibitor to factor VIII/IX is considered the most severe complication associated with the treatment of hemophilia. Inhibitors are allo antibodies (IgG) that neutralize exogenous factors VIII/IX.

Downloads

Published

2023-04-17

Issue

Vol. 2 No. 4 (2023): APRIL

Section

Articles